Who is eligible for clinical trial NCT03305341?

Participants must meet protocol criteria for Covid19. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03305341 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-08

Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix (NCT03305341)

🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

🩺 Plain-English Summary (8th-Grade Level)

Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (9 items).

Location: Medicine Invention Design Incorporation (MIDI) - IORG0007849 — North Bethesda, Maryland

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Controlled Cancers
Moderate COVID-19
Positive testing by standard RT-PCR assay or equivalent testing
Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion
Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) \> 93% on room air at sea level, heart rate ≥ 90 beats per minute
No clinical signs indicative of Severe or Critical Illness Severity

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
1\. Uncontrolled Cancers
2\. Severe or Critical Illness Severity
3\. Pregnancy
4\. Breast-feeding
5\. The patients with other serious inter-current illness
6\. Serious Allergy
7\. Serious Bleed Tendency
8\. The prohibition of the biological product

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Medicine Invention Design Incorporation (MIDI) - IORG0007849 — North Bethesda, Maryland

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗